P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors

Area of Science:

• Pediatric Oncology
• Cancer Pharmacology
• Molecular Biology

Background:

• Multidrug resistance (MDR) significantly limits treatment efficacy in advanced pediatric liver malignancies.
• P-glycoprotein (P-gP) is a key mediator of MDR, and its antagonism has shown promise in other cancers.
• Investigating P-gP modulators is crucial for improving chemotherapy in pediatric liver cancers.

Purpose of the Study:

• To evaluate the efficacy of P-glycoprotein (P-gP) antagonizers in overcoming multidrug resistance (MDR) in pediatric liver cancer cell lines.
• To determine the impact of P-gP modulation on the response to common chemotherapeutic agents like doxorubicin and cisplatin.
• To assess the influence of tumor differentiation on the effectiveness of P-gP modulation.

Main Methods:

• Utilized one hepatocellular carcinoma (HCC) and three hepatoblastoma (HB) cell lines.
• Exposed cell lines to doxorubicin or cisplatin, with and without three P-gP modulators.
• Assessed cytotoxicity and measured MDR1 gene expression via rT-PCR.

Main Results:

• P-gP modulation enhanced chemotherapy effectiveness in all tested HB cell lines, with greater impact in more differentiated tumors.
• Combined treatment with doxorubicin and PSC 833 showed improved efficacy in the HCC cell line.
• The study demonstrated in vitro potential for P-gP modulators to counteract MDR.

Conclusions:

• P-gP modulation offers a viable strategy to overcome MDR in both HCC and HB cell lines in vitro.
• These findings support further in vivo investigations to explore the therapeutic potential of P-gP antagonizers in pediatric liver malignancies.
• Targeting P-gP could represent a novel approach to enhance chemotherapy outcomes for children with liver cancer.